Dr. Todd Lowary, GlycoNet Scientific Director and Professor of Chemistry, was one of two recipients of the University of Alberta’s University Cup Award on September 28th. This award is the university’s top honour for teaching, research, and community service. The full article may be found on the U of A website: http://www.folio.ca/political-scientist-and-carbohydrate-chemist-share-university-cup-honours/
Catégorie : Network News
GlycoNet heeds the call of federal framework on antimicrobials
Antimicrobial-resistant infections are becoming more frequent and more difficult to treat, and antimicrobial resistance is now recognized as a significant worldwide threat. In response, the Public Health Agency of Canada recently released a document called “Tackling Antimicrobial Resistance and Antimicrobial Use: A Pan-Canadian Framework for Action,” which includes a core component of research and innovation […]
Breaking down the walls to fight MRSA
Antimicrobial drug resistance is a growing problem for Canadians and our neighbours around the globe, and GlycoNet investigators are taking a glycomics-based approach to battling one type of drug-resistant bacteria – methicillin-resistant Staphylococcus aureus (MRSA). “Glycomics research is really important to antibiotics and antibiotic drug discovery. It turns out that glycobiology and glycans in general […]
GlycoNet invests more than $1.2 million in glycomics research funding
GlycoNet is proud to announce funding of more than $1.2 million for four new cutting-edge research projects in areas including immunotherapy, chronic diseases, and immuno-oncology. This spring, GlycoNet invited applications for multidisciplinary research from across the country. After a rigorous review process, four projects were selected and awarded more than $1.2 million for the duration of 1-2 years. Three […]
GlycoNet Investigator Dr. Mona Nemer named Canada’s Chief Science Advisor
Ottawa, September 26, 2017—The Honourable Kirsty Duncan, Minister of Science, made the following statement: “Our government made a promise to Canadians that we would restore science to its rightful place in the federal government. Today, we are keeping that promise by announcing our new Chief Science Advisor, Dr. Mona Nemer. “As a distinguished cardiac researcher, Dr. Nemer […]
Battling a sticky enemy: GlycoNet investigators develop strategies for combating bacterial biofilms
Biofilms are a sticky, slime-like force field that shelter bacteria and fungi within their protective barrier. They are also what often keeps your immune system from getting the job done when fighting infections, and make bacteria and fungi up to 1,000 times more tolerant of antibiotics. But what if scientists could stop these biofilms from […]
Realist Pharma and GlycoNet Announce Collaboration
TORONTO (September 19, 2017) – Realist Pharma (“Realist” or “the Company”) today announced that it has entered into a collaboration and contribution agreement with the Canadian Glycomics Network (“GlycoNet”) to assist in development of Realist’s glycomimetic vaccines targeting multiple cancers. In the context of this agreement, GlycoNet will provide a $250,000 financial contribution as well […]
Edmonton startup wants to put Alberta at epicentre of molecular discoveries
A University of Alberta biotechnology spinoff wants to put Edmonton at the epicentre of molecular discoveries by creating an immense searchable database that could speed up and drive down the cost of research and development. This article originally appeared in the Edmonton Journal on August 16th, 2017: http://edmontonjournal.com/technology/science/edmonton-startup-wants-to-put-alberta-at-epicentre-of-molecular-discoveries By Juris Graney, Edmonton Journal Currently, large pharmaceutical […]
Scientists find new way to attack antibiotic-resistant lung infections
Enzymes used to break down the walls built by microbes By Amina Zafar, CBC News Canadian scientists have discovered a possible way to break through the defences of some antibiotic-resistant respiratory infections. It’s hoped that the findings could someday benefit people with cystic fibrosis and other chronic lung diseases who are at greater risk of infections. The […]
Finding the right molecule in a haystack of life–saving possibilities
Developing a new drug starts with identifying the molecule or “ligand” that can block the molecular target or “receptor” involved in a disease. Even with high throughput screening, finding that one functional ligand for a receptor from a haystack of millions of possible compounds is expensive, high–risk and time–consuming. Converting a promising target into a […]